Oxprenolol 40mg tablets

Ülke: Birleşik Krallık

Dil: İngilizce

Kaynak: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktif bileşen:

Oxprenolol hydrochloride

Mevcut itibaren:

A A H Pharmaceuticals Ltd

ATC kodu:

C07AA02

INN (International Adı):

Oxprenolol hydrochloride

Doz:

40mg

Farmasötik formu:

Oral tablet

Uygulama yolu:

Oral

Sınıf:

No Controlled Drug Status

Reçete türü:

Valid as a prescribable product

Ürün özeti:

BNF: 02040000

Ürün özellikleri

1. NAME OF THE MEDICINAL PRODUCT
Trasicor 40 mg Tablets.
Oxprenolol 40 mg Tablets.
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 40 mg of oxprenolol hydrochloride.
Excipients with known effect:
Sucrose powder
(111.6 mg/tablet)
Wheat starch
(53 mg/tablet)
For the full list of excipients, see section 6.1
3. PHARMACEUTICAL FORM
Film-coated tablets.
White round, biconvex, film-coated tablets with bevelled edges
impressed OXP 40 and no
marking on the other.
4.1 THERAPEUTIC INDICATIONS
Trasicor Tablets are indicated in adults for the treatment of:
Angina Pectoris: For long-term prophylactic use (if necessary nitrates
should be employed for
alleviating acute attacks).
Hypertension: As monotherapy or for use in combination with other
antihypertensives, e.g. with a
diuretic, peripheral vasodilator, calcium channel blocker or ACE
inhibitor.
Disturbances of cardiac rhythm: Especially supraventricular
tachycardia, atrial fibrillation and
digitalis-induced arrhythmias, ventricular tachycardia.
Short-term relief of functional cardiovascular disorders due to
adrenergic hyperactivity: Such as
cardiac neurosis, hyperkinetic heart syndrome and anxiety-induced
cardiovascular disorders.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_ _
The dosage should be individualised. Before raising the dosage, the
heart rate at rest should
always be checked. If it is 50-55 beats/min, the dosage should not be
increased, see
contraindications.
If the maximum recommended dose is insufficient to produce the desired
response appropriate
combined therapy should be considered.
When discontinuing prolonged treatment with a beta-blocker, the
medication should not be
interrupted abruptly, but withdrawn gradually.
Higher doses using conventional Trasicor Tablets may be administered
in two or more divided
doses.
Elderly _ _
No special dosage regime is necessary but concurrent hepatic
insufficiency should be taken into
account.
_Paediatric population _
No adequate experience has been acquired on the use of Trasicor
Tablets in childre